NCT04971499View on ClinicalTrials.gov

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

September 6, 2022

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Melanoma

Interventions

DRUG

Dapansutrile

500 mg tablet

DRUG

Pembrolizumab

Single-use vial containing 100 mg/4 mL of pembrolizumab

Trial Locations (1)

27710

RECRUITING

Duke Cancer Center, Durham

Sponsors

Collaborators (1)

Olatec Therapeutics LLC

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Olatec Therapeutics LLC

INDUSTRY

lead

April Salama, M.D.

OTHER